SCHEMBL14246970

SCHEMBL14246970

Cc1ccc(N(Cc2cccnc2)C(=O)c2sc3ccccc3c2Cl)c(C)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.55
▸ GAA P10253 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ LMNA P02545 7/20 0.49
▸ TP53 P04637 6/20 0.49
▸ F10 P00742 1/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.47
▸ POLB P06746 2/20 0.47
▸ NLRP1 Q9C000 1/20 0.47
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ MAPT P10636 3/20 0.45
▸ CD274 Q9NZQ7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14317875 0.90 LMNA (0.51) HPGDGAAKMT2ALMNATP53
SCHEMBL14317877 0.90 NPSR1 (0.49) HPGDKMT2ALMNATP53F10
SCHEMBL14317880 0.85 SMN1; SMN2 (0.48) HPGDKMT2ALMNATP53F10
SCHEMBL14325654 0.85 LMNA (0.51) HPGDGAAKMT2ALMNATP53
SCHEMBL14246842 0.83 NPSR1 (0.49) HPGDKMT2ALMNATP53F10
SCHEMBL14246812 0.80 NPSR1 (0.50) KMT2ALMNATP53F10NPSR1
SCHEMBL14317872 0.80 DYRK1A (0.56) HPGDGAALMNANPSR1POLB
SCHEMBL14315169 0.79 NPSR1 (0.53) HPGDGAAKMT2ALMNATP53
SCHEMBL14246746 0.77 CD274 (0.54) GAAKMT2ALMNATP53F10
SCHEMBL14246841 0.75 NPSR1 (0.46) GAAKMT2ALMNATP53F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 — — US disclosed
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 — — US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 — — US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 — — US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 — — US disclosed
EP-2720695-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NoNO Inc. (CA) 2014-04-23 — — EP disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 — — WO disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 HPGD 262/4885GAA 970/4885KMT2A 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback